Latest news

• Another R&D flop for Incyte, but Jakafi keeps delivering

  Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,

• AZ expects return to growth this year after 2017 decline

  Mantle cell lymphoma therapy Calquence has a long way to go before it can challenge main rival Imbruvica (ibrutinib) from Johnson &Johnson/AbbVie, but according to AZ is picking up 20%

• Celgene gains French reimbursement for Revlimid in multiple myeloma

  It’s been approved in combination with dexamethasone as a first-line treatment for multiple myeloma in patients who are not eligible for autologous stem cell transplant. ... However, HAS handed Revlimid ASMR V status, equating to ‘no

• Janssen's Imbruvica fails to win NICE backing in lymphoma

  Janssen's Imbruvica fails to win NICE backing in lymphoma. But the agency recommends it on the CDF for another type of cancer. ... Draft guidance from the cost-effectiveness body doesn’t back Imbruvica to treat mantle cell lymphoma (MCL) - an incurable,

• AbbVie and Roche plan Venclexta combo filings in leukaemia

  AbbVie and Roche have ambitions to extend the use of the drug into non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML), picking up a breakthrough designation from the FDA ... 8bn last year in CLL, mantle cell lymphoma (MCL), Waldenström